Comment from Association for Accessible Medicines

Summary: The Association for Accessible Medicines (AAM) supports the Draft Guidance for clarifying FDA expectations for responding to Form 483 observations but requests specific modifications to protect attorney-client privilege and reduce unnecessary administrative burdens. They argue for clearer definitions regarding "response preparers," the removal of mandatory disclosure of outside counsel, and the establishment of more transparent communication channels for scientific disagreements.